SLC5A2 and type 2 diabetes mellitus: The treatment effect of SGLT-2 inhibitors on kidney and cardiovascular outcomes was quantified in a recent collaborative meta-analysis of 13 large Phase 3 clinical trials involving a total of 90,409 patients (82.7% were patients with T2D and 17.3% were patients without T2D) [15].